Loading...
AIXC logo

AIxCrypto Holdings, Inc.NasdaqCM:AIXC Stock Report

Market Cap US$29.1m
Share Price
US$1.37
My Fair Value
n/a
1Y-61.6%
7D-5.5%
Portfolio Value
View

AIxCrypto Holdings, Inc.

NasdaqCM:AIXC Stock Report

Market Cap: US$29.1m

AIxCrypto Holdings (AIXC) Stock Overview

Focuses on building an ecosystem that integrates Artificial Intelligence and blockchain while bridging Web2 and Web3. More details

AIXC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AIXC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

AIxCrypto Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for AIxCrypto Holdings
Historical stock prices
Current Share PriceUS$1.38
52 Week HighUS$8.81
52 Week LowUS$0.92
Beta0.52
1 Month Change11.29%
3 Month Change-2.82%
1 Year Change-61.57%
3 Year Change-97.35%
5 Year Change-99.82%
Change since IPO-99.90%

Recent News & Updates

Analysis Article Dec 30

Is AIxCrypto Holdings (NASDAQ:AIXC) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Recent updates

Analysis Article Dec 30

Is AIxCrypto Holdings (NASDAQ:AIXC) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha Aug 16

Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M

Qualigen Therapeutics press release (NASDAQ:QLGN): Q2 GAAP EPS of -$0.11 beats by $0.06. Revenue of $1.4M (+25.0% Y/Y) beats by $0.05M. As of June 30, 2022, Qualigen Therapeutics had $9.7 million in cash. The Company believes its cash is sufficient to fund its anticipated operations into 2023.
Seeking Alpha Jul 29

Qualigen Therapeutics files mixed shelf offering of up to $150M

Qualigen Therapeutics (NASDAQ:QLGN) on Friday filed for a mixed shelf offering of up to $150M. The company disclosed the offering in a S-3 filing with the U.S. SEC after hours. The offering consists of a combination of common stock, preferred stock, debt securities, warrants, rights and units. Carlsbad, Calif.-based Qualigen (QLGN) develops cancer therapies. QLGN stock was down 2.1% to $0.41 in postmarket trading. It earlier closed -2.8% at $0.42.
Seeking Alpha Jul 06

Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Qualigen Therapeutics (NASDAQ:QLGN) on Wednesday said it would partner China-based Hande Sciences to scale-up manufacturing to support investigational new drug application enabling studies for its QN-302 inhibitor platform. QLGN is developing QN-302 as a potential treatment for a type of pancreatic cancer called pancreatic ductal adenocarcinoma, in addition to other cancers such as prostate. The agreement with Hande provides for process development and scale-up batches of material for QLGN’s toxicology studies on QN-302, which QLGN expects to commence in Q3 2022. QLGN said it is on track to complete its investigational new drug application studies for QN-302 in Q3 and Q4 2022. QLGN stock -0.7% at $0.50 in morning trading.
Analysis Article Mar 08

Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article Nov 23

We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

AIXCUS BiotechsUS Market
7D-5.5%1.2%2.1%
1Y-61.6%41.9%30.6%

Return vs Industry: AIXC underperformed the US Biotechs industry which returned 41.9% over the past year.

Return vs Market: AIXC underperformed the US Market which returned 31% over the past year.

Price Volatility

Is AIXC's price volatile compared to industry and market?
AIXC volatility
AIXC Average Weekly Movement15.2%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: AIXC's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: AIXC's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a10Kevin Richardsonwww.aixcrypto.ai

AIxCrypto Holdings, Inc. focuses on building an ecosystem that integrates Artificial Intelligence and blockchain while bridging Web2 and Web3. Its principal products include the BesTrade DeAI Agent and the AIxC ecosystem products. AIxCrypto Holdings, Inc has a strategic collaboration framework with Chutes AI to explore infrastructure support and technical integration opportunities for AIxC's AI agent and application-layer ecosystem.

AIxCrypto Holdings, Inc. Fundamentals Summary

How do AIxCrypto Holdings's earnings and revenue compare to its market cap?
AIXC fundamental statistics
Market capUS$29.14m
Earnings (TTM)-US$19.53m
Revenue (TTM)n/a
0.0x
P/S Ratio
-1.4x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AIXC income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$19.53m
Earnings-US$19.53m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.97
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.5%

How did AIXC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 09:44
End of Day Share Price 2026/05/07 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AIxCrypto Holdings, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
David BautzZacks Small-Cap Research